Description: Phase I/Ib, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants with Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
Target Patient Population: Any tumor type with FGFR2 or FGFR3 gene abnormalities
Study Design: Study drug is given orally